New data published this month shows that respective of a patient’s risk of stroke or bleeding, treatment with apixaban resulted in a consistent reduction in stroke or systemic embolism and mortality compared to warfarin. Reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with apixaban (Eliquis®) compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. The results were published in this month’s Lancet and the subanalysis evaluated data from 18,201 patients in the ARISTOTLE trial, including 434 patients from the UK, based on patients’ risk of stroke from AF and one or more risk factors.